Decision-making and challenges within the evolving treatment algorithm in spinal muscular atrophy: a clinical perspective.

SMN-augmenting therapies have improved health outcomes for people with SMA and powered the practice of personalised medicine. Within this new proactive diagnostic and treatment paradigm, new phenotypes and different disease trajectories are emerging. Ongoing collaborative research efforts to understand the biology of SMA and define optimal response are critical to refining future approaches.